MAX and plasma cell myeloma: Interestingly, while chr12q24 gains are not present in myeloma, we identified here a significant enrichment of c-MYC/MAX target genes in MM patients characterized by high SETD8 expression, thereby supporting a potential role of this oncogenic pathway in SETD8 deregulation.